Table 3. Subsequent risks of glaucoma in MGUS, MM, Waldenström, and AL amyloidosis patients.

	MGUS				MM				Waldenström				AL amyloidosis
	O	SIR	95% CI		O	SIR	95% CI		O	SIR	95% CI		O	SIR	95% CI
All	512	1.60	1.47	1.75	207	1.11	0.97	1.28	81	1.76	1.40	2.19	118	2.18	1.81	2.62
Gender
Men	227	1.59	1.39	1.81	100	1.13	0.92	1.38	48	1.94	1.43	2.57	62	2.49	1.91	3.19
Women	285	1.61	1.43	1.81	107	1.10	0.90	1.33	33	1.55	1.07	2.18	56	1.92	1.45	2.50
Age at diagnosis (years)
<60	22	1.80	1.13	2.73	12	1.54	0.79	2.69	4	3.20	0.83	8.27	36	7.64	5.35	10.59
60–79	283	1.66	1.47	1.86	120	1.13	0.93	1.35	41	1.76	1.26	2.39	55	1.60	1.20	2.08
80+	207	1.52	1.32	1.74	75	1.05	0.82	1.31	36	1.67	1.17	2.31	27	1.82	1.20	2.65
Subtype
Glaucoma suspect (H40.0)	248	1.78	1.56	2.01	83	1.09	0.87	1.36	38	2.12	1.50	2.91	40	1.63	1.16	2.22
Primary open-angle glaucoma (H40.1)	182	1.35	1.16	1.56	84	1.01	0.81	1.26	29	1.38	0.93	1.99	45	2.01	1.46	2.69
Primary angle-closure glaucoma (H40.2)	8	1.85	0.79	3.66	2	0.73	0.07	2.69	1	1.59	0.00	9.10	1	1.27	0.00	7.26
Glaucoma secondary to other eye disorders (H40.5)	16	2.25	1.28	3.66	9	2.12	0.96	4.04	2	1.80	0.17	6.63	10	8.47	4.04	15.64
Other glaucoma (H40.3, H40.4, H40.6, and H40.8)	4	2.45	0.64	6.35	1	0.95	0.00	5.46	0				9	26.47	12.00	50.47
Glaucoma, unspecified (H40.9)	54	1.66	1.25	2.17	28	1.46	0.97	2.11	11	2.10	1.04	3.78	13	2.74	1.45	4.70

MGUS: Monoclonal gammopathy of undetermined significance; MM: Multiple myeloma.

O = Observed cases; SIR = Standardized incidence ratio; CI = Confidence intervals.

Bold type: 95% confidence interval does not include 1.00.